DelMar Pharmaceuticals Relocates Headquarters to San Diego

DelMar Pharmaceuticals announced the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California.

"Our move to the San Diego area is an important step in the evolution of the Company, as it moves our headquarters to the United States, while also providing us with the ability to tap the local biotechnology talent in San Diego as we continue to progress through the clinical trial process of VAL-083. We look forward to taking full advantage of our new headquarters' location and all of the resources the area offers," according to a statement released from the company.

VAL-083 (dianhydrogalactitol) is a "first-in-class," bifunctional, DNA-targeting agent that introduces inter-strand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers, including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI). DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by common mechanisms of chemoresistance, including MGMT, in cancer cell models and animal studies.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.